



FRIDAY 6 SEPTEMBER 2019

07:15	Industry Symposia 07:15 - 08:45			
09:00	Plenary Scientific Session 1 - CGRP and CGRP mAbs 09:00 - 10:00 09:00-09:15 - Review lecture on CGRP role in migraine: evidence from clinical and preclinical studies (L. Edvinsson, Sweden) 09:15-09:30 - CGRP-mAbs overall efficacy, ability to completely eliminate migraine in some patients but make no difference for others, safety profile, and lack of CNS adverse events. (P.J. Goadsby, UK) 09:30-09:45 - Chronic episodic migraine, vs. chronic migraine: lessons learned from CGRP-mAbs (R. Burstein, USA) 09:45-10:00 - Discussion			
10:00	Plenary Scientific Session 2 - Why is it that almost all drugs and devices developed for the treatment of migraine succeed whereas almost all drugs and devices developed for pain fail? 10:00 - 11:00 10:00-10:15 - Review clinical trials in pain and migraine in the past 20 years. (M. Ferrari, The Netherlands) 10:15-10:30 - Role of primary and secondary outcome measures in defining success and failure. (C. Tassorelli, Italy) 10:30-10:45 - Do we need more relevant clinical trial designs & endpoints for acute and prophylactic migraine treatment? (H-C. Diener, Germany) 10:45-11:00 - Discussion			
11:00	Break and Poster Walk I 11:00 - 12:00			
12:00	IHS Advisory Council 12:00-12:45			
12:45	Break and pick up lunch boxes 12:45 - 13:00			
13:00	Lunch Session 1 - Inflammation and migraine 13:00-14:00 13:00-13:15 - Clinical evidence for role of inflammation and anti-inflammatory drugs in migraine (J. Schoenen, Belgium) 13:15-13:20 - Discussion 13:20-13:35 - The inflammosome story (T. Dalkara, Turkey) 13:35-13:40 - Discussion 13:40-13:55 - Imaging inflammation in animal models of migraine. (A. Schain, USA) 13:55-14:00 - Discussion	Lunch Session 2 - The interplay between genetic and the environmental in paediatric headache 13:00 - 14:00 13:00-13:15 - Role of genetic in migraine onset in childhood (A. Hershey, USA) 13:15-13:30 - Role of environment in migraine onset in childhood (V. Guidetti, Italy) 13:30-13:45 - Does it matter? (A. Gelfand, USA) 13:45-14:00 - Discussion	Lunch Session 3 - Is there a role for endocannabinoids in the treatment of migraine or cluster headache? 13:00-14:00 13:00-13:20 - Cannabinoids: hopes or bluster and potential risks (B. McGeeney, USA) 13:20-13:40 - Endocannabinoids and marijuana: examining the basic science and the therapeutic benefit. (S. Silberstein, USA) 13:40-14:00 - Discussion	IHS fellowships 1 Chairs: S-J Wang and C Diener 13:00-14:00 13:00- 13:15 - Effects of CGRP antagonism on ischemic stroke outcomes in experimental animals (Inge Mulder, Netherlands) 13:15 - 13:30 - Exploring phasic changes of pain determination in migraine. (Kuan-Po Peng, Taiwan) 13:30 - 13:45 - Sulfotransferase inhibitors in the pathophysiology of migraine (Doga Vuralli, Turkey) 13:45 - 14:00 - Deciphering the visual thalamic circuitry that modulates migraine events (Olivier Brock, United Kingdom)
14:00	One Topic Two Views 2 - Novel views on post-traumatic headache 14:00-15:00 14:00-14:05 - Chairman Introduction Chairman questions: How can post-traumatic headache trigger chronic migraine if migraine is a genetic disorder? 14:05-14:25 - Post-traumatic headache is NOT a primary headache with head trauma as a trigger (T. Schwedt, USA) 14:25-14:45 - Psychogenic vs. neurogenic origin of post-traumatic headache. (G. Ifergan, Israel) 14:45-15:00 - Discussion	One Topic Two Views 3 - Behavioral animal models of migraine: are we wasting our time? 14:00-15:00 14:00-14:05 - Chairman Introduction 14:05-14:25 - Behavioral animal model are not good enough to predict what will happen in the clinic (T. Ward, USA) 14:25-14:45 - Behavioral animal model are good enough to predict what will happen in the clinic (A. van den Maagdenberg, The Netherlands) 14:45-15:00 - Discussion	One Topic Two Views 1 - Are functional or structural brain changes cause or result of migraine and can they predict progression of disease? 14:00 - 15:00 14:00-14:05 - Chairman Introduction 14:05-14:20 - Structural brain changes are real and permanent (G. Terwindt, The Netherlands) 14:20-14:35 - Brain state vs. Brain trait (D. Borsook, USA) 14:35-14:50 - fMRI studies cannot predict progression of disease years before it occurs (A. Hougaard, Denmark) 14:50-15:00 - Discussion	Exhibition Open 09:00 - 17:30
15:00	Plenary Scientific Session 3 - IASP/IHS: Crosstalk between social interactions and pain behavior 15:00 - 16:00 Moderator: Arne May and Allen Finely 15:00-15:15 - Headache in social context (D. Buse, USA) 15:15-15:30- Adolescents with chronic pain: Getting by with a little help from my friends 15:30-15:45 - The importance of the social context in pain experience and expression 15:45-16:00 - Discussion		Paediatrics session- Uncommon, but important headache disorders in Childhood 15:00-16:00 Migraine with motor aura- investigation and amnagement (I. Abu Arefeh, United Kingdom) Thunderclap Headache in adolescents (P. Prabhakar, London) Primary Stabbing Headache (M. Valeriani, Italy)	
16:00	Break 16:00 - 16:15			
16:15	One Topic Two Views 4 - Is aura a brain-damaging event? 16:15-17:15 16:15-16:20 - Chairman introduction 16:20-16:35 - Aura/CSD effect on vasculature and brain parenchyma (K.C. Brennan, USA) 16:35-16:50 - Aura and CSD are events that damage the brain and its vasculature – possible explanation for the increase risk of stroke (T. Kurth, Germany) 16:50-17:05 - Migraine aura: clinical implications for brain health (C. Ayata, USA) 17:05-17:15 - Discussion	One Topic Two Views 5 - Is cardiovascular risk a marketing gimmick or a real factor in treatment options? 16:15-17:15 16:15-16:20 - Chairman Introduction 16:20-16:40 - Cardiovascular risk in migraine and the implications for treatment options (A. Maassen van den Brink, The Netherlands) 16:40-17:00 - Cardiovascular risk does not commonly prevent the use of triptans (S. Sacco, Italy) 17:00-17:15 - Discussion	One Topic Two Views 6 - CGRP mAbs and CGRP receptor antagonists site of action 16:15 - 17:15 16:15-16:20 - Chairman Introduction 16:20-16:40 - The central action of CGRP-mAb is the main reason for its efficacy (A. Charles, USA) 16:40-17:00 - The peripheral action of CGRP-mAb is the main reason for its efficacy (G. Dussor USA) 17:00-17:15 - Discussion	
17:15	Industry Symposia 17:15 - 18:45			
19:00				

Colour Key	Sessions
Green	Teaching Courses
Light Blue	Plenary Sessions
Orange	Parallel Sessions - debate sessions proposal to include 2 x speakers 20 mins each, chairman 10 mins, Q&A 10 mins
Dark Blue	Industry Symposia
Yellow	Exhibition
Light Green	AGM
Light Blue	Oral Communications
Dark Blue	Cephalalgia Award Lecture / Awards and Closing Ceremony
Red	Coffee break / Lunch / Poster Walk
Grey	Social Activities